CoreValve, Inc. has been acquired by Medtronic, Inc.
The founder of CoreValve, Inc. has sold the company to Medtronic, Inc. for US$700 million plus additional payments contingent upon the achievement of agreed milestones.
CoreValve was founded in 2001 and performed its first human transcatheter valve procedure in 2004. Its ReValving System received CE Mark approval in 2007 and has since become a technology leader in percutaneous aortic valve replacement. The ReValving System is comprised of a porcine pericardial tissue value, mounted on a self-expanding frame and implanted via a low profile (18F) delivery catheter. CoreValve is based in Irvine, California.
Medtronic is the world leader in medical technology providing lifelong solutions for people with chronic disease. They offer products, therapies and services that enhance or extend the lives of millions of people. Each year, five million patients benefit from Medtronic's technology, used to treat conditions such as diabetes, heart disease, neurological disorders and vascular illnesses.
Oaklins' team in France advised the seller in this transaction.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more